European Respiratory Review,
Год журнала:
2024,
Номер
33(171), С. 230143 - 230143
Опубликована: Янв. 17, 2024
The
treatable
traits
approach
represents
a
strategy
for
patient
management.
It
is
based
on
the
identification
of
characteristics
susceptible
to
treatments
or
predictive
treatment
response
in
each
individual
patient.
With
objective
accelerating
progress
research
and
clinical
practice
relating
such
approach,
Portraits
event
was
convened
Barcelona,
Spain,
November
2022.
Here,
while
reporting
key
concepts
that
emerged
from
discussions
during
meeting,
we
review
current
state
art
related
chronic
respiratory
diseases
management,
describe
possible
actions
clinicians
can
take
implement
framework.
Furthermore,
explore
new
concept
GETomics
models
field
COPD.
European Respiratory Journal,
Год журнала:
2023,
Номер
61(4), С. 2300239 - 2300239
Опубликована: Март 1, 2023
Executive
summary
of
the
Global
Strategy
for
Prevention,
Diagnosis
and
Management
COPD
2023:
latest
evidence-based
strategy
document
from
Initiative
Chronic
Obstructive
Lung
Disease
(GOLD)
https://bit.ly/3KCaTGe
American Journal of Respiratory and Critical Care Medicine,
Год журнала:
2022,
Номер
206(11), С. 1317 - 1325
Опубликована: Авг. 1, 2022
"Definition
and
Nomenclature
of
Chronic
Obstructive
Pulmonary
Disease:
Time
for
Its
Revision."
American
Journal
Respiratory
Critical
Care
Medicine,
206(11),
pp.
1317–1325
American Journal of Respiratory and Critical Care Medicine,
Год журнала:
2021,
Номер
205(3), С. 275 - 287
Опубликована: Окт. 21, 2021
Chronic
obstructive
pulmonary
disease
(COPD)
is
the
end
result
of
a
series
dynamic
and
cumulative
gene-environment
interactions
over
lifetime.
The
evolving
understanding
COPD
biology
provides
novel
opportunities
for
prevention,
early
diagnosis,
intervention.
To
advance
these
concepts,
we
propose
therapeutic
trials
in
two
major
groups
subjects:
"young"
individuals
with
those
pre-COPD.
Given
that
lungs
grow
to
about
20
years
age
begin
at
approximately
50
years,
consider
patients
range
20-50
years.
Pre-COPD
relates
any
who
have
respiratory
symptoms
or
without
structural
and/or
functional
abnormalities,
absence
airflow
limitation,
may
develop
persistent
limitation
time.
We
exclude
from
current
discussion
infants
adolescents
because
their
unique
physiological
context
older
adults
given
representation
prior
randomized
controlled
(RCTs).
highlight
need
RCTs
focused
on
young
pre-COPD
reduce
progression,
providing
innovative
approaches
identifying
engaging
potential
study
subjects.
detail
RCT
design,
including
outcomes
such
as
lung
function,
patient-reported
outcomes,
exacerbations,
imaging,
mortality,
composite
endpoints.
critically
review
design
components
statistical
powering
analysis,
duration
treatment,
formats
trial
structure,
platform,
basket,
umbrella
trials.
provide
call
action
treatment
The Journal of Allergy and Clinical Immunology In Practice,
Год журнала:
2022,
Номер
10(11), С. 2783 - 2797
Опубликована: Май 7, 2022
Globally,
around
half
the
adult
asthma
population
are
current
or
former
cigarette
smokers.
Cigarette
smoking
and
interact
to
induce
an
"asthma-smoking
phenotype(s),"
which
has
important
implications
for
diagnosis,
pathogenic
mechanisms,
management.
The
lack
of
progress
in
understanding
effects
on
adults
with
is
due
part
their
exclusion
from
most
investigative
studies
large
clinical
trials.
In
this
review,
we
summarize
adverse
outcomes
associated
asthma,
highlight
challenges
diagnosing
among
smokers
chronic
respiratory
symptoms,
particularly
older
individuals
a
long-standing
history,
review
mechanisms
involving
smoking-
asthma-related
airway
inflammation,
tissue
remodeling,
corticosteroid
insensitivity,
low-grade
systemic
inflammation.
We
discuss
key
components
management
including
importance
cessation
strategies,
evidence
effectiveness
Global
Initiative
Asthma
recommendations
treatment
smokers,
role
treatable
traits
such
as
type
2
eosinophilic
Lastly,
provide
algorithm
aid
clinicians
manage
asthma.
future,
controlled
pragmatic
trials
real-world
populations
should
include
base
recommendations.
